PMID- 21987803 OWN - NLM STAT- MEDLINE DCOM- 20111230 LR - 20211020 IS - 1091-6490 (Electronic) IS - 0027-8424 (Print) IS - 0027-8424 (Linking) VI - 108 IP - 42 DP - 2011 Oct 18 TI - Resistance to thyroid hormone is modulated in vivo by the nuclear receptor corepressor (NCOR1). PG - 17462-7 LID - 10.1073/pnas.1107474108 [doi] AB - Mutations in the ligand-binding domain of the thyroid hormone receptor beta (TRbeta) lead to resistance to thyroid hormone (RTH). These TRbeta mutants function in a dominant-negative fashion to interfere with the transcription activity of wild-type thyroid hormone receptors (TRs), leading to dysregulation of the pituitary-thyroid axis and resistance in peripheral tissues. The molecular mechanism by which TRbeta mutants cause RTH has been postulated to be an inability of the mutants to properly release the nuclear corepressors (NCORs), thereby inhibiting thyroid hormone (TH)-mediated transcription activity. To test this hypothesis in vivo, we crossed Thrb(PV) mice (a model of RTH) expressing a human TRbeta mutant (PV) with mice expressing a mutant Ncor1 allele (Ncor1(DeltaID) mice) that cannot recruit a TR or a PV mutant. Remarkably, in the presence of NCOR1DeltaID, the abnormally elevated thyroid-stimulating hormone and TH levels found in Thrb(PV) mice were modestly but significantly corrected. Furthermore, thyroid hyperplasia, weight loss, and other hallmarks of RTH were also partially reverted in mice expressing NCOR1DeltaID. Taken together, these data suggest that the aberrant recruitment of NCOR1 by RTH TRbeta mutants leads to clinical RTH in humans. The present study suggests that therapies aimed at the TR-NCOR1 interaction or its downstream actions could be tested as potential targets in treating RTH. FAU - Fozzatti, Laura AU - Fozzatti L AD - Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. FAU - Lu, Changxue AU - Lu C FAU - Kim, Dong Wook AU - Kim DW FAU - Park, Jeong Won AU - Park JW FAU - Astapova, Inna AU - Astapova I FAU - Gavrilova, Oksana AU - Gavrilova O FAU - Willingham, Mark C AU - Willingham MC FAU - Hollenberg, Anthony N AU - Hollenberg AN FAU - Cheng, Sheue-yann AU - Cheng SY LA - eng GR - DK-056123/DK/NIDDK NIH HHS/United States GR - R56 DK056123/DK/NIDDK NIH HHS/United States GR - R01 DK078090/DK/NIDDK NIH HHS/United States GR - ImNIH/Intramural NIH HHS/United States GR - R01 DK056123/DK/NIDDK NIH HHS/United States GR - DK-078090/DK/NIDDK NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, N.I.H., Intramural DEP - 20111010 PL - United States TA - Proc Natl Acad Sci U S A JT - Proceedings of the National Academy of Sciences of the United States of America JID - 7505876 RN - 0 (NCOR1 protein, human) RN - 0 (Ncor1 protein, mouse) RN - 0 (Nuclear Receptor Co-Repressor 1) RN - 0 (Thyroid Hormone Receptors beta) RN - 0 (Thyroid Hormones) SB - IM MH - Animals MH - Disease Models, Animal MH - Genes, erbA MH - Humans MH - Male MH - Mice MH - Mice, Mutant Strains MH - Mice, Transgenic MH - Mutation MH - Nuclear Receptor Co-Repressor 1/chemistry/genetics/*physiology MH - Protein Structure, Tertiary MH - Sequence Deletion MH - Thyroid Hormone Receptors beta/genetics/physiology MH - Thyroid Hormone Resistance Syndrome/*genetics/pathology/*physiopathology MH - Thyroid Hormones/blood/physiology PMC - PMC3198316 COIS- The authors declare no conflict of interest. EDAT- 2011/10/12 06:00 MHDA- 2011/12/31 06:00 PMCR- 2012/04/18 CRDT- 2011/10/12 06:00 PHST- 2011/10/12 06:00 [entrez] PHST- 2011/10/12 06:00 [pubmed] PHST- 2011/12/31 06:00 [medline] PHST- 2012/04/18 00:00 [pmc-release] AID - 1107474108 [pii] AID - 201107474 [pii] AID - 10.1073/pnas.1107474108 [doi] PST - ppublish SO - Proc Natl Acad Sci U S A. 2011 Oct 18;108(42):17462-7. doi: 10.1073/pnas.1107474108. Epub 2011 Oct 10.